Closer inspection of TCGA PanCancer Atlas cohorts revealed that, although amplification at the HRAS locus is surprisingly rare, SCCs express significantly higher levels of HRAS than adenocarcinomas, and HRAS mRNA is overexpressed in around 30%, 25%, and 10% of cases of HNSCC, UC, and LSCC, respectively (Figure 1). Here, HRAS is linked to adenocarcinoma.